News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Swedish Orphan Biovitrum Gets FDA Approval to Manufacture Substance for Kineret® With Partner Boehringer Ingelheim Corporation



6/11/2013 9:14:25 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Swedish Orphan Biovitrum AB (publ) (Sobi) today announced receipt of approval from the Food and Drug Administration (FDA) for the manufacture of drug substance for Kineret® (anakinra) at Boehringer Ingelheim's microbial site in Vienna, Austria. The approval allows for distribution of Kineret in the US, and comes as the result of a Supplemental Biologics License Application (sBLA) filed with the FDA in February 2013.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES